Neutrophile granulocyte membrane coated metal coordination nanoparticle drug as well as construction method and application thereof
Through the neutrophil membrane coated with metal-coordinated nanoparticle drugs, combined with the mechanism of ferrodysfunction and IDO inhibitors, the problem of insufficient stability and targeting of nanodrugs in clinical applications is solved, and effective treatment of advanced liver cancer is achieved and immune activation significantly improve the tumor treatment effect.
Patent Information
- Application Number
- CN202410985964.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-23
AI Technical Summary
In clinical applications, existing nanodrugs have problems such as rapid in vivo clearance, insufficient biostability and poor targeting performance, making it difficult to effectively treat advanced liver cancer.
The nanoparticle obtained by reacting sorafenib and trivalent iron with 4-phenylimidazole is used to form SRF-FePI@NEM nanoparticle , using the combined effect of ferrodysfunction mechanism and IDO inhibitors to achieve killing and immune activation of targeted tumor cells.
This nanodrug can effectively target liver cancer cells, activate immunotherapy, enhance anti-tumor immunity, reduce the toxic side effects of normal cells, improve the tumor treatment effect, and achieve responsive drug release in an acidic environment.
Smart Images

Figure CN118903048A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of nano-biomedicine, and relates to a neutrophil membrane-coated metal-coordinated nano-particle medicine, a construction method and an application thereof. Background Art
[0002] Cancer is considered one of the most aggressive malignancies in humans. Common treatments for advanced liver cancer are chemotherapy and targeted therapy, depending on the status of actionable driver mutations. In addition to traditional tumor treatments, various new nanobiomaterials have attracted attention due to their enhanced anti-tumor properties and low off-target effects. However, nanomedicines have certain limitations in clinical applications, including rapid in vivo clearance, insufficient biological stability, and poor targeting performance. Therefore, it is necessary to develop nanodrug delivery systems with similar composition to organisms to circumvent these defects.
[0003] The drug delivery system constructed by cell membrane takes advantage of the natural biological membrane and shows great potential in the field of tumor treatment. Considering that immune cells play a role in almost every stage of tumor metastasis, people have proposed a coating method using immune cell membranes, which has unique tumor homing ability and superior biocompatibility. Among them, neutrophils (NE) are the most abundant white blood cells in the mammalian circulation, accounting for 50-70% of the total circulating white blood cells, and are the first white blood cells recruited to the site of inflammation. The drug delivery system based on neutrophil membrane (NEM) can improve the effect of cancer treatment, has the advantages of immune evasion and prolonged circulation, can enhance the accumulation of drugs at the tumor site, and improve the immunosuppression of the tumor microenvironment.
[0004] Tumor ferroptosis is a non-apoptotic form of regulated cell death characterized by the accumulation of iron-dependent lipid peroxides (LPO). Ferroptosis differs from other types of cell death in both mechanism and morphology, and is characterized by cytoplasmic swelling and cell membrane rupture, while the nucleus shows little morphological change. Due to the non-apoptotic nature of the ferroptosis pathway, ferroptosis-based tumor therapy may bypass defects such as drug resistance. The Fenton reaction involved in ferroptosis requires free divalent iron to generate reactive oxygen species (ROS) represented by hydroxyl radicals. The accumulated ROS peroxidize membrane lipids, causing loss of cell function and cell death. Therefore, iron is a crucial redox-active component in the regulation of ferroptosis. Sorafenib (SRF), an oral multikinase inhibitor, was first approved as a standard first-line treatment for advanced liver cancer. It can inhibit vascular endothelial growth factor receptor 1 / 2 / 3 (VEGFR-1 / 2 / 3), platelet-derived growth factor receptor (PDGFR-β), Fms-like tyrosine kinase 3 (Flt-3) and stem cell growth factor (c-KIT), inhibiting tumor angiogenesis and tumor development.
[0005] In addition to directly killing tumor cells, clinical research is currently focusing on the tumor microenvironment. It is reported that the main factor for poor tumor treatment results from the immunosuppressive microenvironment. Tumors can escape immune surveillance and easily metastasize in this environment. It has been observed that immune checkpoints are associated with the immunosuppressive environment. Immune checkpoints such as indoleamine-2,3-dioxygenase (IDO) can suppress immune responses and promote tumor development. IDO inhibitors can reprogram the host inflammatory environment, turning "cold" tumors (non-T cell inflammatory tumors) into "hot" tumors (T cell inflammatory tumors). The metabolism of tryptophan plays an important role in ferroptosis treatment. More tryptophan plays an inhibitory role in the development of tumors, while IDO inhibitors can inhibit the conversion of tryptophan, thereby maintaining a higher concentration of tryptophan, promoting the occurrence of ferroptosis, and playing an enhanced anti-tumor effect of combined treatment. Summary of the invention
[0006] In view of the problems in the above-mentioned background technology, the object of the present invention is to provide a neutrophil membrane-coated metal coordination nanoparticle drug and a construction method and application thereof.
[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0008] A neutrophil membrane-coated metal-coordinated nanoparticle drug, wherein the metal-coordinated nanoparticle is SRF-FePI particle obtained by the reaction of SRF, trivalent iron and PI (full name: 4-phenylimidazole).
[0009] The particle size range of the neutrophil membrane-coated metal coordination nanoparticle drug is about 137.2±4.1 nm.
[0010] The method for constructing the neutrophil membrane-coated metal coordination nanoparticle drug comprises the following steps:
[0011] (1) SRF solution and Fe 3+ The mixture was fully mixed with the PI solution, and then precipitated by adding water and centrifuged to obtain nanoparticles SRF-FePI;
[0012] (2) NE was extracted from mouse bone marrow, and NEM nanovesicles were obtained by ultrasonic centrifugation and extrusion;
[0013] (3) The nanoparticles are co-extruded with NEM nanovesicles to obtain the nanoparticles.
[0014] Further,
[0015] Step (1) The solvent of SRF is DMSO, Fe 3+ The solvent for PI was methanol;
[0016] Fe 3+The concentration of the solution is 18-108 mg / mL; the concentration of the PI solution is 18-108 mg / mL, the concentration of the SRF solution is 11.25-108 mg / mL, and the concentration of the Fe 3+ The volume ratio of SRF to Fe solution is 1:2 to 1:8. 3+ The volume ratio of the solution ranges from 1:2 to 1:8.
[0017] Optimum: SRF solution is first mixed with Fe 3+ The solutions were mixed, and then the mixed solution was added dropwise to the PI solution, and the reaction was stirred at room temperature for at least 1 h.
[0018] The specific method of step (2) is as follows:
[0019] 1) Take mouse bone marrow cells and resuspend them in 1×PBS; add red blood cell lysis buffer, incubate on ice for 3 minutes, centrifuge at 1500 rpm for 5 minutes at 25°C, discard the supernatant and resuspend the cells in 1×PBS;
[0020] 2) Carefully add 55%, 65%, and 78% (v / v) Percoll working solutions into the centrifuge tube in sequence (due to the different densities of the working solutions, a three-layer gradient will be formed, and no direct stratification will be performed), and add the bone marrow cell suspension to the top layer; centrifuge at 2000 rpm for 30 minutes, collect the cells between the 65% and 78% gradients, wash and centrifuge, and resuspend in 1× PBS;
[0021] 3) Ultrasonic treatment for 5 min in an ice water bath, centrifuge at 5800 rpm for 5 min, discard the precipitate; centrifuge at 15000 rpm for 30 min at 4°C, and wash the precipitate with PBS;
[0022] 4) Using a liposome extruder, extrude the liposomes through a 400 nm polycarbonate membrane back and forth for at least 14 times (after each extrusion, return and extrude again) to obtain NEM nanovesicles.
[0023] The specific preparation method of the Percoll working solution in step 2) is as follows: Percoll cell separation solution (purchased from: Solebo Company) and 10×PBS are prepared in a volume ratio of 9:1 to prepare Percoll stock solution, and then Percoll stock solution and 1×PBS are used to prepare 55%, 65%, and 78% (v / v) working solutions.
[0024] The specific method of step (3) is as follows: weigh 1-2 mg SRF-FePI, add 1 mL ultrapure water and ultrasonically treat for at least 5 minutes to prepare a uniformly dispersed suspension, mix with the same mass of NEM vesicles, and ultrasonically treat for 2 minutes (ultrasonication for 2 seconds, stop for 3 seconds, energy 30%, power 500w); then co-extrude at least 14 times through a liposome extruder under a 200nm polycarbonate membrane; centrifuge at 12000rpm for 10 minutes, wash the precipitate, and obtain.
[0025] The present invention also provides the use of the neutrophil membrane-coated metal coordination nanoparticle medicine in the preparation of liver cancer therapeutic medicine.
[0026] Beneficial Effects
[0027] 1. The present invention prepares a drug of neutrophil membrane-coated metal-coated nanoparticles, which is used to kill liver cancer cells (HepG2) and enhance immunotherapy. Neutrophil membranes are coated on the surface of nanomedicines, which have the function of escaping the clearance of macrophages (RAW 264.7), can target tumor cells, have a good killing effect on liver cancer cells, and inhibit the conversion of tryptophan, thereby activating the immunosuppressive microenvironment and exerting enhanced anti-tumor immunity.
[0028] 2. The nano-drug provided by the present invention utilizes coordination bonds to form a drug delivery carrier, which is loaded with sorafenib for the treatment of liver cancer and responsively releases free drugs when it reaches the acidic environment of tumor cells.
[0029] 3. Both the free drugs and nano drugs involved in the present invention have low toxic side effects on normal liver cells (L02) and have good biocompatibility. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 FeCl 3 6H 2 Infrared spectra of O, PI, SRF and SRF-FePI nanomedicine prepared by the present invention.
[0031] Figure 2 The transmission electron microscope image (a) and elemental analysis images (b-f) of the SRF-FePI@NEM nanomedicine prepared by the present invention show that the synthesized nanomedicine has a membrane-core structure.
[0032] Figure 3 It is a particle size distribution diagram of the SRF-FePI@NEM nanomedicine prepared by the present invention.
[0033] Figure 4 It is the cumulative drug release amount of the SRF-FePI and SRF-FePI@NEM nanomedicines prepared by the present invention in PBS solutions at pH 7.4 and pH 5.1.
[0034] Figure 5 It is the fluorescence intensity diagram of high-content imaging detection of SRF-FePI and SRF-FePI@NEM nanomedicine uptake in HepG2 cells and RAW264.7.
[0035] Figure 5 In the experiment, the fluorescent dye Nile red (NR) was used to replace 50% of SRF as a fluorescent tracer for high-content imaging observation.
[0036] Figure 6 The present invention is a study on the cytotoxicity of SRF, SRF-FePI prepared by the present invention and SRF-FePI@NEM nanomedicines to HepG2 cells and L02 cells.
[0037] Figure 7 It is a Calcein-AM / PI double staining picture of HepG2 cells and L02 cells by SRF, SRF-FePI prepared by the present invention and SRF-FePI@NEM nanomedicine.
[0038] Figure 8 It is a fluorescence intensity diagram of the ROS generation ability of the SRF-FePI@NEM nanomedicine prepared by the present invention detected by high-content imaging.
[0039] Fig. 9 It is a graph of kynurenine inhibition of PI, SRF-FePI prepared by the present invention and SRF-FePI@NEM nanomedicine. DETAILED DESCRIPTION
[0040] In order to better illustrate the present invention, the present invention is further described below in conjunction with embodiments.
[0041] Example 1: Preparation and characterization of nanomedicine SRF-FePI@NEM
[0042] (1) Weigh 20 mg SRF and dissolve it in 120 μL DMSO to obtain a drug stock solution. Weigh 33.8 mg FeCl 3 6H 2 O and 72.1 mg PI were dissolved in 1 mL methanol. 3+ The methanol solution was mixed, and the mixed solution was then added dropwise to the PI solution, and the reaction was stirred at room temperature for 1 hour. After the reaction was completed, 1 mL of pre-cooled ultrapure water was added dropwise to terminate the reaction and allow solids to precipitate. The product was washed twice by centrifugation (4°C, 10000 rpm, 20 min), and finally freeze-dried at -50°C for 5 hours to obtain a yellow solid powder product, which was SRF-FePI nanoparticles. The infrared spectrum test was performed on it, and the results were as follows: Figure 1 shown.
[0043] (2) ICR mice were anesthetized and killed by cervical dislocation. The femur and tibia were removed, and the bone marrow was washed with RPMI 1640 medium and filtered with a 75 μm cell strainer. The cell suspension was centrifuged at 1500 rpm for 5 min, and the bone marrow cells at the bottom of the centrifuge tube were collected and resuspended with 1× PBS. Red blood cell lysis buffer was added, incubated on ice for 3 min, centrifuged at 1500 rpm for 5 min at 25°C, the supernatant was discarded, and the cells were resuspended in 1× PBS. 55%, 65%, and 78% (v / v) Percoll working solutions were added to the centrifuge tube, and the bone marrow cell suspension was added to the top layer. Centrifuged at 2000 rpm for 30 minutes, the cells between the 65% and 78% gradient were collected, washed, centrifuged and resuspended. Ultrasonic treatment was performed in an ice water bath for 5 min, and centrifuged at 3200 g for 5 min at 4°C, and the precipitate was discarded to discard unbroken cell nuclei and cells. Centrifuged at 20000 g for 30 min at 4°C, and the precipitate was washed with PBS. The NEM nanovesicles were obtained by extruding the liposomes through a 400 nm polycarbonate membrane 14 times using a liposome extruder.
[0044] (3) Weigh 2 mg of SRF-FePI using an analytical balance, add 1 mL of ultrapure water and sonicate for 5 min to prepare a uniformly dispersed suspension. After diluting to 900 μg / mL, mix with the same mass of NEM vesicles and sonicate for 2 min. Then co-extrude 14 times under a 200 nm polycarbonate membrane through a liposome extruder. Centrifuge at 12,000 rpm for 10 min, remove the unloaded cell membrane in the supernatant, and obtain SRF-FePI@NEM nanomedicine. The nanomedicine was dispersed in water and placed under a transmission electron microscope for observation, and elemental scanning analysis was performed. The results are as follows: Figure 2 The particle size distribution of nanomedicine was detected by dynamic light scattering, and the results were as follows Figure 3 shown.
[0045] Example 2: Characterization of pH-responsive release performance of nanodrug SRF-FePI@NEM
[0046] Prepare two release media with different pH values: (1) PBS containing 40% ethanol (pH 7.4) (2) PBS containing 40% ethanol (pH 5.1). Dilute SRF-FePI and SRF-FePI@NEM with release medium to a nanoparticle concentration of 450 μg / mL. Take 1 mL and add it to the dialysis bag of each group. Clamp the dialysis bag with dialysis clamps at 3 to 5 cm on both ends, place it in a centrifuge tube, and add 30 mL of release medium with different pH values. Take out 1 mL of release medium at a specific time point and immediately add 1 mL of fresh release medium PBS with the corresponding pH value. Use high performance liquid chromatography to detect the drug content of SRF and PI. Calculate the cumulative release of the drug according to the formula, and the results are as follows: Figure 4As shown, compared with the neutral pH 7.4 environment, the release rate and cumulative release amount of the drug-loaded system in the acidic pH 5.1 environment are higher, which shows that the system constructed in the present invention has a certain pH-responsive release performance.
[0047] V n V is the volume of each sample (mL); 0 is the initial volume of the release medium (mL); C n is the sample concentration of the nth sampling (μg / mL); m D is the initial mass of drug added.
[0048]
[0049] Example 3: Cellular uptake experiment of nanodrug SRF-FePI@NEM
[0050] (1) The cellular uptake ability of the nanodrug SRF-FePI@NEM was investigated using RAW 264.7 and HepG2 cells. Since the nanodrug itself has no fluorescence, 50% SRF was replaced with the fluorescent dye NR as a fluorescent tracer marker during the preparation process. The centrifugal speed (8000rpm) and centrifugal time (10min) were reduced to remove free NR. The prepared fluorescent complex NR-FePI was then extruded to modify the neutrophil membrane on the outer layer to prepare the biomimetic nano fluorescent complex NR-FePI@NEM.
[0051] (2) RAW 264.7 or HepG2 cells were cultured at 1×10 5 / hole or 3×10 4 / well were inoculated in a 96-well plate and incubated overnight. The culture medium was discarded, and the same concentration of drugs NR-FePI and NR-FePI@NEM (measured in SRF concentration) were added. After incubation for 4 hours, the culture medium was aspirated, and the cells were washed twice with DPBS or PBS to remove free drugs. Then 100 μL of Hoechst33342 with a concentration of 1 μg / mL was added to stain the nucleus for 10 minutes, washed once, and finally 100 μL of DMEM was added to each well for high-content imaging. The results are shown in Figure 5 As shown, the cell membrane-coated fluorescent composite nanoparticles NR-FePI@NEM are more likely to be taken up by HepG2 cells than uncoated NR-FePI, indicating that the SRF-FePI@NEM constructed by the present invention has the ability to target inflammation to liver cancer cells after the membrane modification of NEM, which is beneficial to the targeted delivery of drugs. The uptake of cell membrane-coated nanoparticles by RAW 264.7 cells is significantly reduced because the surface NEM also acts as an immune cell, plays a role in cell membrane camouflage, and can escape the phagocytosis of RAW 264.7 cells.
[0052] Example 4: Cytotoxicity experiment of nanomedicine SRF-FePI@NEM
[0053] HepG2 or L02 cells were cultured at 3×10 4 / hole or 1×10 4 / well was inoculated in a 96-well plate, and the medium was discarded after incubation for 24 hours. The drug was diluted with blank medium to 50, 25, 12.5, 6.25, 3.125, 1, and 0.1 μg / mL. 100 μL of medium containing the drug was added to each well of the experimental group, and a blank group (containing only blank medium) and a control group (cells + blank medium) were set up, with 5 replicate wells in each group. After incubation for 24 hours, the medium was discarded, and 100 μL of 10% CCK-8 solution was added and incubated for 1 hour. The absorbance at 450 nm was detected by an enzyme reader. The results are as follows Figure 6 As shown, with the increase of drug concentration, the viability of HepG2 cells decreased to varying degrees. The free drug SRF has a certain cytotoxicity to HepG2 cells. The drug-carrying system SRF-FePI provides the inducer and excess iron ions required for tumor ferroptosis, and has a better killing effect on tumors than free SRF. In addition, the IC50 of the drug-carrying system SRF-FePI@NEM after modifying the cell membrane structure is 1-3.125μg / mL. When the concentration reaches 50μg / mL, the cell survival rate of HepG2 is only 15.5%, and the toxic effect on liver cancer cells is better. The possible reason is that SRF-FePI@NEM is more easily taken up by HepG2 cells, and the efficiency of drug delivery is higher. In addition, the survival rates of SRF, SRF-FePI, SRF-FePI@NEM and L02 cells co-incubated with L02 cells of the present invention are all above 80%, and there are no obvious toxic side effects on normal liver cells L02 cells.
[0054] Example 5: Calcein-AM / PI experiment of SRF-FePI@NEM nanomedicine
[0055] HepG2 or L02 cells were cultured at 3×10 4 / hole or 1×10 4 / well was inoculated in a 96-well plate, and the medium was discarded after incubation for 24 hours. 100 μL of 25 μg / mL or 50 μg / mL blank medium diluted with drugs SRF, SRF-FePI, SRF-FePI@NEM (all converted to SRF concentration) was added to each well. After incubation for 24 hours, the medium was slowly aspirated and 100 μL of calcein double staining reagent was added. After staining for 30 minutes, high-content imaging was performed. The results are shown in Figure 7 As shown, SRF-FePI@NEM has a better killing effect on HepG2 cells, so the red fluorescence distribution of dead cells accounts for a large proportion, and the distribution of dead cells has exceeded half, and the results are consistent with the cytotoxicity results.
[0056] Example 6: ROS generation experiment of SRF-FePI@NEM nanomedicine
[0057] HepG2 cells were cultured at 3×10 4 / well were inoculated in a 96-well plate, and the culture medium was discarded after incubation overnight. 100 μL of the drug SRF-FePI@NEM (SRF final concentration was 12.5 μg / mL) diluted with blank culture medium was added to stimulate the cells to produce ROS, and 100 μL of blank culture medium was added to the control group. Then 100 μL of DCFH-DA probe with a final concentration of 5 μM was added, and the drug and fluorescent probe were incubated with the cells for 2 hours. After the incubation, the culture medium was aspirated and washed three times with PBS to wash away the drugs that were not taken into the cells and the excess fluorescent probes, and then 100 μL of DMEM culture medium was added for high-content imaging. The results are shown in Figure 8 As shown, the experimental group showed fluorescence, indicating that SRF-FePI@NEM produced ROS in HepG2 cells, while the blank group did not show green fluorescence.
[0058] Example 7: Kynurenine inhibition experiment of nanomedicine SRF-FePI@NEM
[0059] HepG2 cells were cultured at 1×10 4 / well was inoculated in a 96-well plate, and the culture medium was discarded after incubation for 24 hours. Drugs PI, SRF-FePI, and SRF-FePI@NEM diluted in DMEM culture medium were added, and four concentrations of 1μM, 10μM, 50μM, and 100μM were set respectively, and 3 replicate wells were set in each group. 25μL of INF-γ with a final concentration of 50ng / mL (to stimulate the expression of IDO) and 25μL of tryptophan with a final concentration of 1.2mM (to provide reaction raw materials) were added to each well. After incubation for 48 hours, 140μL of supernatant was taken out to a centrifuge tube, and the subsequent experimental steps remained the same as above. After color development with Ehrlich reagent, the absorbance at 490nm was measured with an enzyme reader. The results are shown as follows Fig. 9 As shown, the nano drug SRF-FePI@NEM after modifying the cell membrane has a good Kyn inhibition effect in HepG2 cells, and the inhibition rate gradually increases with the increase of drug concentration. The Kyn inhibition rate of SRF-FePI@NEM with a concentration of 1000μM can reach 80%. In the SRF-FePI@NEM constructed by the present invention, more Trp reaction raw materials are retained in the cells in HepG2 cells, indicating that the IDO pathway is inhibited. The delivered drug PI acts as an IDO inhibitor, which blocks the IDO pathway by inhibiting the possibility of Trp conversion to Kyn, activates T cells, improves the ability of pathogens to clear infections, and induces the body's immune response.
[0060] The results of Examples 4 to 7 above demonstrate that the present invention has an inhibitory effect on liver cancer cells.
[0061] The above embodiments are preferred implementation modes of the present invention, which are only used to illustrate the technical solutions of the present invention rather than to limit the present invention. It should be understood that there are many alternative solutions within the scope of the principle of the present invention, which do not affect the essential content of the present invention.
Claims
1. A neutrophil membrane-coated metal-coordinated nanoparticle drug, characterized in that: The metal coordinated nanoparticles are SRF-FePI particles obtained by the reaction of SRF, trivalent iron and PI.
2. The method for constructing the neutrophil membrane-coated metal-coordinated nanoparticle drug according to claim 1, characterized in that: The following steps are involved: (1) SRF solution and Fe 3+ The mixture was fully mixed with the PI solution, and then precipitated by adding water and centrifuged to obtain nanoparticles SRF-FePI; (2) NE was extracted from mouse bone marrow, and NEM nanovesicles were obtained by ultrasonic centrifugation and extrusion; (3) The nanoparticles are co-extruded with NEM nanovesicles to obtain the nanoparticles.
3. The construction method according to claim 2, characterized in that: Step (1) The solvent of SRF is DMSO, Fe 3+ The solvent for PI was methanol; Fe 3+ The concentration of the solution is 18-108 mg / mL; the concentration of the PI solution is 18-108 mg / mL, the concentration of the SRF solution is 11.25-108 mg / mL, and the concentration of the Fe 3+ The volume ratio of SRF to Fe solution is 1:2 to 1:
8. 3+ The volume ratio of the solution ranges from 1:2 to 1:
8.
4. The construction method according to claim 2 or 3, characterized in that: The SRF solution was first mixed with Fe 3+ The solutions were mixed, and then the mixed solution was added dropwise to the PI solution, and the reaction was stirred at room temperature for at least 1 h.
5. The construction method according to claim 2, characterized in that: The specific method of step (2) is as follows: 1) Take mouse bone marrow cells and resuspend them in 1×PBS; add red blood cell lysis buffer, incubate on ice for 3 minutes, centrifuge at 1500 rpm for 5 minutes at 25°C, discard the supernatant and resuspend the cells in 1×PBS; 2) 55%, 65%, and 78% (v / v) Percoll working solutions were added to the centrifuge tube in sequence, and the bone marrow cell suspension was added to the top layer; centrifuged at 2000 rpm for 30 minutes, the cells between 65% and 78% of the gradient were collected, washed and centrifuged, and resuspended in 1× PBS; 3) Ultrasonic treatment for 5 min in an ice water bath, centrifuge at 5800 rpm for 5 min, discard the precipitate; centrifuge at 15000 rpm for 30 min at 4°C, and wash the precipitate with PBS; 4) Using a liposome extruder, extrude the liposome through a 400 nm polycarbonate membrane for at least 14 times to obtain NEM nanovesicles.
6. The construction method according to claim 5, characterized in that: The specific preparation method of the Percoll working solution in step 2) is as follows: Percoll cell separation solution and 10×PBS are used in a volume ratio of 9:1 to prepare Percoll stock solution, and then Percoll stock solution and 1×PBS are used to prepare 55%, 65%, and 78% (v / v) working solutions.
7. The construction method according to claim 2, characterized in that: The specific method of step (3) is as follows: weigh 1-2 mg SRF-FePI, add 1 mL ultrapure water and ultrasonically treat for at least 5 minutes to prepare a uniformly dispersed suspension, mix with NEM vesicles of the same mass as SRF-FePI, and ultrasonically treat for 2 minutes, ultrasonicate for 2 seconds, stop for 3 seconds, energy 30%, power 500w; then co-extrude at least 14 times through a liposome extruder under a 200nm polycarbonate membrane; centrifuge at 12000rpm for 10 minutes, wash the precipitate, and obtain.
8. Use of the neutrophil membrane-coated metal coordination nanoparticle drug prepared by the method according to claim 1 or any one of claims 2 to 7 in preparing a drug for treating liver cancer.
Citation Information
Patent Citations
Microcapsule for microwave sensitization tumor treatment, and preparation method and application thereof
CN104069087A
Nano-drug with tumor immune microenvironment regulation function as well as preparation method and application of nano-drug
CN115702889A
Cell membrane bionic nano-vesicle for expressing transferrin as well as preparation method and application of cell membrane bionic nano-vesicle
CN116144600A
Nano-enabled immunotherapy in cancer
WO2018213631A1
Nano-drug having tumor immunity microenvironment regulation function, preparation method therefor, and application thereof
WO2023010776A1
